Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma — Masatoshi Kudo (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma
Shared by
Masatoshi Kudo
Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma
Article
2021
en
Authors
Masatoshi Kudo
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2001
Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC)
Josep M. Llovet
,
María Isabel Real
,
R. Vilana
,
Ramón Planas
,
S. Coll
,
John J. Aponte
,
Carmen Ayuso
,
María Sala
,
Jordi Muchart
,
R. Costa
,
J Rodés
,
Jordi Bruix
Journal of Hepatology
Article
2019
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka
,
Takashi Kumada
,
Masanori Atsukawa
,
Masashi Hirooka
,
Kunihiko Tsuji
,
Toru Ishikawa
,
Koichi Takaguchi
,
Kazuya Kariyama
,
Ei Itobayashi
,
Kazuto Tajiri
,
Noritomo Shimada
,
Hiroshi Shibata
,
Hironori Ochi
,
Toshifumi Tada
,
Hidenori Toyoda
,
Kazuhiro Nouso
,
Akemi Tsutsui
,
Takuya Nagano
,
Norio Itokawa
,
Korenobu Hayama
,
Michitaka Imai
,
Kouji Joko
,
Hironori Tanaka
,
Tsutomu Tamai
,
Yohei Koizumi
,
Yoichi Hiasa
,
Kojiro Michitaka
,
Masatoshi Kudo
Editorial Material
2023
Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo
Article
2023
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
Masatoshi Kudo
,
Richard S. Finn
,
Tim Meyer
,
Frédéric Boisserie
,
Songzi Li
,
Yaxi Chen
,
Ramil Abdrashitov
,
Andrew X. Zhu
,
Arndt Vogel
,
Shukui Qin
Dataset
Supplementary Material for: Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka
,
Takashi Kumada
,
Masanori Atsukawa
,
Masashi Hirooka
,
Keita Tsuji
,
Toru Ishikawa
,
Koichi Takaguchi
,
Kazuya Kariyama
,
Ei Itobayashi
,
Kazuto Tajiri
,
Naohiko Shimada
,
Hiroshi Shibata
,
Hironori Ochi
,
Toshifumi Tada
,
Hideki Toyoda
,
Kazuhiro Nouso
,
Akemi Tsutsui
,
Takuya Nagano
,
Norio Itokawa
,
Koremasa Hayama
,
Michitaka Imai
,
Kouji Joko
,
Hironori Tanaka
,
T. Tamai
,
Yuma Koizumi
,
Yoichi Hiasa
,
Kojiro Michitaka
,
Masatoshi Kudo
,
Real-Life Practice Experts For HCC Study Group
,
HCC Group
Discussion(0)
No comments yet. Be the first to comment.